WCM Investment Management’s Krystal Biotech KRYS Stock Holding History

WCM Investment Management’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.96M	Buy	+15,753	New	+$4.71M	0.01%	175

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

WCM Investment Management's KRYS Position: Q2 2026 in Review

WCM Investment Management opened a new position in Krystal Biotech (KRYS) in Q2 2026: 15,753 shares worth $5.96M. The stake represents 0.01% of the portfolio and ranks #175 among its holdings.

422 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

WCM Investment Management held 15,753 shares of Krystal Biotech worth $5.96M as of Q2 2026.
Krystal Biotech was a new WCM Investment Management position in Q2 2026.
Krystal Biotech made up 0.01% of WCM Investment Management's portfolio in Q2 2026, its #175 holding.
422 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on WCM Investment Management's 13F filing for Q2 2026, filed 13 Aug 2026.